{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:56:49Z","timestamp":1791633409466,"version":"4.3.4"},"reference-count":103,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.reuma.2017.08.007","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T05:31:11Z","timestamp":1509168671000},"page":"254-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Recomendaciones de la Sociedad Espa\u00f1ola de Reumatolog\u00eda sobre el tratamiento y uso de terapias sist\u00e9micas biol\u00f3gicas y no biol\u00f3gicas en artritis psori\u00e1sica"],"prefix":"10.1016","volume":"14","author":[{"given":"Juan Carlos","family":"Torre Alonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"D\u00edaz del Campo Fontecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Almod\u00f3var","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Montilla Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamaida","family":"Plasencia-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ram\u00edrez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Queiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2017.08.007_bib0520","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0525","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/BOR.0000000000000155","article-title":"Targeting extra-articular manifestations in PsA: A closer look at enthesitis and dactylitis","volume":"27","author":"Siegel","year":"2015","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0530","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0535","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","article-title":"Concepts of pathogenesis in psoriatic arthritis: Genotype determines clinical phenotype","volume":"17","author":"FitzGerald","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reuma.2017.08.007_bib0540","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0545","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: Current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0550","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: A systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0555","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrrheum.2015.184","article-title":"Psoriatic arthritis in 2015: Advancement continues in imaging, tight control and new drugs","volume":"12","author":"Olivieri","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0560","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0565","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0570","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.reuma.2011.02.001","article-title":"Documento SER de consenso sobre el uso de terapias biol\u00f3gicas en la artritis psori\u00e1sica","volume":"7","author":"Fern\u00e1ndez-Sueiro","year":"2011","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2017.08.007_bib0575","unstructured":"Sociedad Espa\u00f1ola de Reumatolog\u00eda. Grupo de trabajo ESPOGUIA. Gu\u00eda de pr\u00e1ctica cl\u00ednica para el tratamiento de la espondiloartritis axial y la artritis psori\u00e1sica. [monograf\u00eda en Internet]. Madrid: Sociedad Espa\u00f1ola de Reumatolog\u00eda; 2015."},{"key":"10.1016\/j.reuma.2017.08.007_bib0580","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/1744666X.2016.1193436","article-title":"Improvements in diagnostic tools for early detection of psoriatic arthritis","volume":"12","author":"D\u2019Angelo","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0585","doi-asserted-by":"crossref","first-page":"C102","DOI":"10.12968\/hmed.2016.77.7.C102","article-title":"Psoriatic arthritis","volume":"77","author":"Durham","year":"2016","journal-title":"Br J Hosp Med (Lond)."},{"key":"10.1016\/j.reuma.2017.08.007_bib0590","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.reuma.2016.03.005","article-title":"Multidisciplinary care models for patients with psoriatic arthritis","volume":"13","author":"Queiro","year":"2017","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2017.08.007_bib0595","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00296-017-3702-9","article-title":"Identification and management of comorbidity in psoriatic arthritis: Evidence- and expert-based recommendations from a multidisciplinary panel from Spain","volume":"37","author":"Torre Alonso","year":"2017","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.reuma.2017.08.007_bib0600","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis","volume":"65","author":"Di Minno","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.reuma.2017.08.007_bib0605","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/art.22531","article-title":"The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients","volume":"57","author":"Leeb","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0610","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.2010.129379","article-title":"Development of a preliminary composite disease activity index in psoriatic arthritis","volume":"70","author":"Mumtaz","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0615","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0620","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0625","doi-asserted-by":"crossref","first-page":"5281052014","DOI":"10.1155\/2014\/528105","article-title":"Disease activity in psoriatic arthritis: Comparison of the discriminative capacity and construct validity of six composite indices in a real world","volume":"2014","author":"Salaffi","year":"2014","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.reuma.2017.08.007_bib0630","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3899\/jrheum.090956","article-title":"Composite measures in psoriatic arthritis: GRAPPA 2008","volume":"37","author":"Gladman","year":"2010","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0635","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3899\/jrheum.140172","article-title":"Composite disease activity and responder indices for psoriatic arthritis: A report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response","volume":"41","author":"Helliwell","year":"2014","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0640","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3899\/jrheum.140178","article-title":"Outcomes research in psoriasis and psoriatic arthritis using large databases and research networks: A report from the GRAPPA 2013 Annual Meeting","volume":"41","author":"Armstrong","year":"2014","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0645","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3899\/jrheum.140312","article-title":"Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations","volume":"42","author":"Van den Bosch","year":"2015","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0650","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3899\/jrheum.090234","article-title":"Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs","volume":"83","author":"Cantini","year":"2009","journal-title":"J Rheumatol Suppl."},{"key":"10.1016\/j.reuma.2017.08.007_bib0655","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/rheumatology\/ken059","article-title":"Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs","volume":"47","author":"Cantini","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2017.08.007_bib0660","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/acr.20162","article-title":"Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.reuma.2017.08.007_bib0665","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0670","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3899\/jrheum.141156","article-title":"Enhanced patient involvement and the need to revise the core set \u2014 Report from the Psoriatic Arthritis Working Group at OMERACT 2014","volume":"42","author":"Tillett","year":"2015","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0675","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.berh.2014.10.004","article-title":"Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis","volume":"28","author":"Machado","year":"2014","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0680","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0685","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/ard.2009.117945","article-title":"Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis","volume":"69","author":"Nell-Duxneuner","year":"2010","journal-title":"Ann Rheum Dis."},{"issue":"10012","key":"10.1016\/j.reuma.2017.08.007_bib0690","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.reuma.2017.08.007_bib0695","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3899\/jrheum.140179","article-title":"GRAPPA treatment recommendations: An update from the GRAPPA 2013 Annual Meeting","volume":"41","author":"Coates","year":"2014","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0700","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.22884","article-title":"High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors","volume":"57","author":"Gonzalez-Juanatey","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0705","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0710","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0715","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0720","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2012-202608","article-title":"Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis","volume":"72","author":"Tillett","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0725","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2011.150938","article-title":"Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?","volume":"70","author":"Gladman","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0730","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0735","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","article-title":"Early psoriatic arthritis: Short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)","volume":"73","author":"Theander","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0740","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10067-007-0787-7","article-title":"The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: Results of a pilot randomised 6-month trial with methotrexate","volume":"27","author":"Scarpa","year":"2008","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0745","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2017.08.007_bib0750","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/ard.2009.113308","article-title":"Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis","volume":"69","author":"Lie","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0755","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202641","article-title":"Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials","volume":"73","author":"Goulabchand","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0760","first-page":"469","article-title":"Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort","volume":"35","author":"Chandran","year":"2008","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0765","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0770","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1759720X10381432","article-title":"Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases","volume":"2","author":"Schett","year":"2010","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0775","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0780","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0785","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.140647","article-title":"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis","volume":"42","author":"Kavanaugh","year":"2015","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0790","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for \u2265156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0795","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","article-title":"Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.reuma.2017.08.007_bib0800","doi-asserted-by":"crossref","first-page":"i137","DOI":"10.1093\/rheumatology\/keu115.004","article-title":"Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure","volume":"53","author":"Mease","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2017.08.007_bib0805","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0810","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.reuma.2017.08.007_bib0815","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0820","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0825","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","article-title":"Brief Report: Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis","volume":"68","author":"Van der Heijde","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0830","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.reuma.2017.08.007_bib0835","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.reuma.2015.05.001","article-title":"2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis","volume":"11","author":"Sanmart\u00ed","year":"2015","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2017.08.007_bib0840","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","article-title":"Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: A systematic review of the literature","volume":"54","author":"Behrens","year":"2015","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2017.08.007_bib0845","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0850","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0855","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0860","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ."},{"key":"10.1016\/j.reuma.2017.08.007_bib0865","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3899\/jrheum.151290","article-title":"Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: Results from 2 clinical trials","volume":"43","author":"Combe","year":"2016","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0870","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0875","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2012-202035","article-title":"Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0880","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0885","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0890","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: Results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0895","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2","volume":"56","author":"Van der Heijde","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0900","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0905","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: Results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0910","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: Results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 10","key":"10.1016\/j.reuma.2017.08.007_bib0915","first-page":"S145","article-title":"Comparing adalimumab and etanercept as first line agents in patients with psoriatic arthritis: data from the Rheumadata_ clinical database and registry [abstract]","volume":"65","author":"Hoa","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0920","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0925","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2017.08.007_bib0930","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: Data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0935","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: Results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.08.007_bib0940","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: A cohort study from Southern Sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0945","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jbspin.2014.08.001","article-title":"Treatment response, drug survival and safety of anti-tumour necrosis factor alpha therapy in 193 patients with psoriatic arthritis: a twelve-year \u00abreal life\u00bb experience","volume":"82","author":"Soubrier","year":"2015","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.reuma.2017.08.007_bib0950","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/ard.2007.082925","article-title":"Sustained response to long-term biologics and switching in psoriatic arthritis: Results from real life experience","volume":"67","author":"Coates","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0955","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/annrheumdis-2015-eular.2351","article-title":"Efficacy of switching tumor necrosis factor \u03b1 inhibitor to a second tumor necrosis factor \u03b1 inhibitor and the influence of drug levels and anti-drug antibodies in patients with ankylosing spondylitis and psoriatic arthritis","volume":"74","author":"Ruwaard","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0960","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3899\/jrheum.100069","article-title":"Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: Effectiveness and safety results from an open-label study","volume":"37","author":"Gladman","year":"2010","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0965","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/annrheumdis-2014-eular.1499","article-title":"Efficacy and safety of brodalumab over one year in patients with psoriatic arthritis with and without prior exposure to a biologic","volume":"73","author":"Genovese","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0970","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.140878","article-title":"Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis","volume":"41","author":"Orbai","year":"2014","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0975","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3899\/jrheum.140879","article-title":"Comprehensive treatment of dactylitis in psoriatic arthritis","volume":"41","author":"Rose","year":"2014","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.08.007_bib0980","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.reuma.2010.12.002","article-title":"[Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis]","volume":"7","author":"Juanola Roura","year":"2011","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2017.08.007_bib0985","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib0990","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2017.08.007_bib0995","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: Post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib1000","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term i-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.08.007_bib1005","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 2","key":"10.1016\/j.reuma.2017.08.007_bib1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.13542","article-title":"Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"30","author":"Daud\u00e9n","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.reuma.2017.08.007_bib1015","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.rdc.2015.07.008","article-title":"Comorbidities in psoriatic arthritis","volume":"41","author":"Husni","year":"2015","journal-title":"Rheum Dis Clin North Am."},{"key":"10.1016\/j.reuma.2017.08.007_bib1020","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/rheumatology\/keu461","article-title":"Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis","volume":"54","author":"Gonz\u00e1lez-\u00c1lvaro","year":"2015","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2017.08.007_bib1025","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/acr.22404","article-title":"Qualifying unmet needs and improving standards of care in psoriatic arthritis","volume":"66","author":"Helliwell","year":"2014","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.reuma.2017.08.007_bib1030","first-page":"269","article-title":"Position paper from the Spanish Society of Rheumatology on biosimilar drugs","volume":"11","author":"Abad Hern\u00e1ndez M\u00c1","year":"2015","journal-title":"Reumatol Clin."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X17302310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X17302310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T03:29:46Z","timestamp":1719545386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X17302310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1699258X17302310"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2017.08.007","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones de la Sociedad Espa\u00f1ola de Reumatolog\u00eda sobre el tratamiento y uso de terapias sist\u00e9micas biol\u00f3gicas y no biol\u00f3gicas en artritis psori\u00e1sica","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2017.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}